Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update

Hematopoietic cell transplant (HCT) can cure both children and adults with sickle cell disease. Outcomes have historically been poor for the vast majority of patients who lack a matched sibling donor. However, the development of haploidentical HCT (haplo-HCT) with high doses of posttransplant cyclop...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Dilan A., Akinsete, Adeseye M., de la Fuente, Josu, Kassim, Adetola A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118612/
https://www.ncbi.nlm.nih.gov/pubmed/32202252
http://dx.doi.org/10.1016/j.hemonc.2020.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118612/
https://www.ncbi.nlm.nih.gov/pubmed/32202252
http://dx.doi.org/10.1016/j.hemonc.2020.01.002

Ejemplares similares